February 14, 2019 06:36 AM EST
R&D

As­traZeneca sweeps away the Med­Im­mune name as CEO So­ri­ot re­struc­tures R&D

John Carroll

Editor & Founder

Med­Im­mune is his­to­ry.

As­traZeneca ex­ecs ac­knowl­edged to­day that the com­pa­ny is sweep­ing the Med­Im­mune brand name away as CEO Pas­cal So­ri­ot stream­lines the R&D or­ga­ni­za­tion, carv­ing the group in­to 2 parts.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times